Trade Neurocrine Biosciences, Inc. - NBIX CFD

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Latest shares articles

Alibaba price forecast: Third-party price targets
On 26 March 2025, the price of Alibaba (BABA) shares had increased by approximately 57.49% year-to-date (YTD) and 89.75% year on year. 
10:15, 30 April 2025
Amazon Q1 Preview: AI Ambitions Under Scrutiny Amid Trade Policy Headwinds and Margin Pressures
Amazon (AMZN) is set to report its Q1 2025 results after the close on May 1, with investors closely watching how the e-commerce and cloud giant is navigating a more challenging macroeconomic environment.
10:01, 30 April 2025
Apple Q2 Earnings Preview: US trade policy risks profit margins and China sales
Apple (AAPL) is scheduled to report its fiscal second-quarter (Q2 FY2025) results after the close on May 1, with investors weighing slowing demand trends against renewed geopolitical risks, notably the reemergence of US-China trade tensions.
14:33, 29 April 2025
Meta set to report Q1 earnings as ad-pricing headwinds test growth outlook
Meta Platforms (META) is scheduled to report its fiscal first-quarter earnings after the market closes on April 30. The social media giant heads into the results under pressure to maintain its growth trajectory amid emerging ad-pricing challenges and a softening macroeconomic environment.
09:22, 29 April 2025

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2024-10-22
infoaamon

Very trustworthy and affordable for any size trades

2024-10-21
remi74

It is very easy to connect with TradingView but the web interface is also great.

2024-10-15
jdancer37

Easy to use and great support. Been using it for 2 years already and still happy

2024-10-14
DANIEL

Capital.com is one of the best stock trading platforms I’ve used. The UX and UI on both the mobile app and web platform are outstanding, making it incredibly easy to navigate. They’ve built a vibrant community of traders and investors, and their UAE team really stands out for delivering an exceptional trading experience.

2024-10-08
Yahyaamez

Best broker!! they call you to see if you need any help. The app is good and nice better than the rest

2024-10-04
Iuliia Salivon

Great app! I requested some features to be added, such as analysis tools, and they delivered. Amazing job! The agents are always helpful and reply quickly. It’s not 5 stars because, at times, some less experienced agents may say it’s impossible to fulfill the request or fix the problem while another agent, like Angel, quickly escalated the issue to the necessary team/person/department and resolved it

2024-10-04
Moh ST

This is an excellent platform. The stop loss and take profit work very well; however, when the changes are very fast like at the beginning of the session, the stop loss does not work. If this defect is corrected it will be the perfect platform.

2024-09-30
adenysenko24

-Nice -Easy to use - Beautiful Interface

2024-09-26
Daniel

I think I'm new in this trading platform, but I find it affordable and most reliable. To be honest I'm not fully experienced trader, but with very limited knowledge of trading I try learn as much as I can by trying out different platforms see if can make money. My interests growing in you platform, l like news updates you also short videos on YouTube, other propaganda, poster and many more. I will see what happens in the coming months. Thanks capital team.

2024-09-26
John Fallows

Gives you options to start learning how too do it as it gives you a demo option to learn from your mistakes

2024-09-24
PHEMELO

Efficiency. When creating the account, it was smooth, efficient from start to finish. Verification of documents also was done the same day, unlike other platforms where you have to wait a day or two.

2024-09-04
Osondu Paul

From what I'm seeing it's cool Mixing it with trading view it's perfect... I didn't give it 5 star yet cos I still need to use it for some time

Showing our 4 & 5 star reviews

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading